Cara Short Term Debt vs Total Current Liabilities Analysis

CARA Stock  USD 0.26  0.01  3.70%   
Cara Therapeutic financial indicator trend analysis is way more than just evaluating Cara Therapeutic prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cara Therapeutic is a good investment. Please check the relationship between Cara Therapeutic Short Term Debt and its Total Current Liabilities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.

Short Term Debt vs Total Current Liabilities

Short Term Debt vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cara Therapeutic Short Term Debt account and Total Current Liabilities. At this time, the significance of the direction appears to have weak relationship.
The correlation between Cara Therapeutic's Short Term Debt and Total Current Liabilities is 0.34. Overlapping area represents the amount of variation of Short Term Debt that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Cara Therapeutic, assuming nothing else is changed. The correlation between historical values of Cara Therapeutic's Short Term Debt and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Debt of Cara Therapeutic are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Short Term Debt i.e., Cara Therapeutic's Short Term Debt and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.34
Relationship DirectionPositive 
Relationship StrengthVery Weak

Short Term Debt

Total Current Liabilities

Total Current Liabilities is an item on Cara Therapeutic balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Cara Therapeutic are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.
Most indicators from Cara Therapeutic's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cara Therapeutic current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.Tax Provision is expected to grow at the current pace this year, whereas Selling General Administrative is forecasted to decline to about 15.7 M.
 2021 2022 2023 2024 (projected)
Total Operating Expenses112.1M122.1M136.3M77.9M
Cost Of Revenue1.6M7.3M6.2M5.9M

Cara Therapeutic fundamental ratios Correlations

0.120.740.750.980.810.01-0.28-0.690.60.340.83-0.22-0.570.980.540.870.860.940.190.70.890.50.020.980.59
0.120.680.230.00.540.750.16-0.690.720.58-0.120.22-0.690.140.690.370.380.080.950.210.360.790.820.160.5
0.740.680.750.630.920.44-0.12-0.950.950.60.44-0.16-0.870.750.890.840.850.680.750.710.860.880.50.770.71
0.750.230.750.620.80.03-0.13-0.650.680.280.54-0.18-0.610.760.580.720.70.730.390.660.740.760.060.770.34
0.980.00.630.620.71-0.06-0.31-0.60.490.290.85-0.25-0.460.950.450.790.790.930.050.640.810.35-0.060.940.53
0.810.540.920.80.710.44-0.16-0.920.850.560.6-0.24-0.90.780.830.820.830.720.660.740.880.840.470.810.74
0.010.750.440.03-0.060.440.33-0.490.470.310.110.26-0.53-0.090.440.090.11-0.10.680.140.180.510.99-0.060.44
-0.280.16-0.12-0.13-0.31-0.160.330.19-0.14-0.71-0.030.720.29-0.33-0.34-0.35-0.38-0.080.08-0.53-0.30.070.32-0.36-0.31
-0.69-0.69-0.95-0.65-0.6-0.92-0.490.19-0.95-0.68-0.40.290.94-0.69-0.94-0.85-0.87-0.59-0.76-0.72-0.89-0.81-0.54-0.73-0.85
0.60.720.950.680.490.850.47-0.14-0.950.660.29-0.27-0.890.610.940.780.80.520.770.710.810.850.530.650.7
0.340.580.60.280.290.560.31-0.71-0.680.66-0.01-0.47-0.760.380.790.570.590.130.620.630.530.50.370.420.66
0.83-0.120.440.540.850.60.11-0.03-0.40.29-0.010.02-0.260.710.170.570.570.75-0.120.450.640.220.060.70.39
-0.220.22-0.16-0.18-0.25-0.240.260.720.29-0.27-0.470.020.42-0.26-0.47-0.3-0.36-0.090.04-0.66-0.370.060.25-0.31-0.4
-0.57-0.69-0.87-0.61-0.46-0.9-0.530.290.94-0.89-0.76-0.260.42-0.57-0.96-0.71-0.75-0.43-0.81-0.76-0.78-0.81-0.58-0.61-0.81
0.980.140.750.760.950.78-0.09-0.33-0.690.610.380.71-0.26-0.570.570.90.870.950.230.690.880.53-0.061.00.56
0.540.690.890.580.450.830.44-0.34-0.940.940.790.17-0.47-0.960.570.740.770.430.790.80.780.780.510.620.78
0.870.370.840.720.790.820.09-0.35-0.850.780.570.57-0.3-0.710.90.740.970.770.430.740.970.620.150.910.78
0.860.380.850.70.790.830.11-0.38-0.870.80.590.57-0.36-0.750.870.770.970.740.440.780.970.610.160.890.82
0.940.080.680.730.930.72-0.1-0.08-0.590.520.130.75-0.09-0.430.950.430.770.740.160.530.770.49-0.080.940.4
0.190.950.750.390.050.660.680.08-0.760.770.62-0.120.04-0.810.230.790.430.440.160.340.440.880.760.260.54
0.70.210.710.660.640.740.14-0.53-0.720.710.630.45-0.66-0.760.690.80.740.780.530.340.80.490.160.740.69
0.890.360.860.740.810.880.18-0.3-0.890.810.530.64-0.37-0.780.880.780.970.970.770.440.80.620.220.910.83
0.50.790.880.760.350.840.510.07-0.810.850.50.220.06-0.810.530.780.620.610.490.880.490.620.580.540.48
0.020.820.50.06-0.060.470.990.32-0.540.530.370.060.25-0.58-0.060.510.150.16-0.080.760.160.220.58-0.030.47
0.980.160.770.770.940.81-0.06-0.36-0.730.650.420.7-0.31-0.611.00.620.910.890.940.260.740.910.54-0.030.61
0.590.50.710.340.530.740.44-0.31-0.850.70.660.39-0.4-0.810.560.780.780.820.40.540.690.830.480.470.61
Click cells to compare fundamentals

Cara Therapeutic Account Relationship Matchups

Cara Therapeutic fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets233.0M271.2M247.1M182.2M125.8M136.4M
Other Current Liab10.6M10.4M8.5M10.0M14.0M14.7M
Total Current Liabilities42.9M18.5M17.6M23.5M25.6M17.5M
Total Stockholder Equity186.7M249.0M227.5M158.8M57.1M112.3M
Property Plant And Equipment Net3.7M5.1M3.6M2.0M8.2M8.6M
Net Debt(14.0M)(26.4M)(9.8M)(61.8M)(8.6M)(9.0M)
Retained Earnings(400.7M)(392.3M)(480.8M)(566.2M)(684.7M)(650.5M)
Accounts Payable9.1M4.9M5.6M9.6M11.6M12.2M
Cash18.3M31.7M13.5M63.7M51.8M54.4M
Non Current Assets Total67.3M76.1M73.8M13.3M9.7M9.2M
Cash And Short Term Investments155.0M180.9M167.0M145.4M100.8M104.8M
Net Receivables1.8M2.1M1.2M4.5M4.0M4.2M
Common Stock Total Equity39K47K50K53K61.0K33.2K
Common Stock Shares Outstanding42.7M47.9M50.7M53.7M54.1M35.8M
Short Term Investments136.7M149.2M153.6M81.7M49.0M93.8M
Liabilities And Stockholders Equity233.0M271.2M247.1M182.2M125.8M136.4M
Non Current Liabilities Total3.4M3.7M1.9M11.5M43.2M45.3M
Other Current Assets9.7M12.1M2.5M16.7M8.6M5.3M
Other Stockholder Equity587.2M641.2M708.6M726.6M742.0M395.3M
Total Liab46.2M22.2M19.5M23.5M68.8M72.2M
Property Plant And Equipment Gross3.7M5.1M3.6M2.0M9.9M10.3M
Total Current Assets165.7M195.1M173.3M168.9M116.2M112.2M
Accumulated Other Comprehensive Income170K73K(358K)(1.7M)(260K)(273K)
Common Stock39K47K50K53K54K35.2K
Property Plant Equipment700K840K631K426K383.4K364.2K
Net Tangible Assets190.1M252.7M229.4M158.8M182.6M155.7M
Retained Earnings Total Equity(400.7M)(392.3M)(480.8M)(566.2M)(509.6M)(484.1M)
Capital Surpluse587.2M641.2M708.6M726.6M835.6M525.5M
Net Invested Capital186.7M249.0M227.5M158.8M57.1M54.2M
Net Working Capital122.8M176.6M155.7M145.5M90.6M142.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Cara Therapeutic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cara Therapeutic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cara Therapeutic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cara Therapeutic Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.71)
Revenue Per Share
0.202
Quarterly Revenue Growth
(0.86)
Return On Assets
(0.63)
Return On Equity
(1.84)
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.